Wire · operational-macro
South Africa's Aspen sells menopause treatment rights for $220 million but keeps 10-year ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
Aspen Pharmacare has sold the European commercial rights to its menopause treatment product Ovestin to Ennogen Healthcare International for about $220 million but retains manufacturing and supply contracts for 10 years, supporting Aspen's strategic focus on emerging markets and debt reduction.
This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it between 2 Nov 2026 and 3 Nov 2026.
◆ ◆ The Wire takeaway
Aspen’s decision to sell European rights but keep manufacturing means you have time to approach Ennogen for new partnerships while still relying on Aspen’s supply chain. This opens a potential window to negotiate with both players if you operate in women’s health pharma or supply services.
◆ Coverage
2 sources · first reported 2 Nov 2026 · latest 3 Nov 2026
◆ Related on Wire
◆ Topics